Compare Enveric Biosciences Inc (ENVB) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs J M Smucker Co — how do they compare? Enveric Biosciences Inc trades at $1.42 (market cap $5.32M), while J M Smucker Co trades at $112.85 (market cap $11.65B). The key difference: J M Smucker Co is far larger — about 2189.8× Enveric Biosciences Inc's market cap, and J M Smucker Co pays a 4.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SJM | |
|---|---|---|
Market Cap | $5.32M | $11.65B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $117.05 |
52-Week Low | $1.28 | $89.53 |
Enterprise Value | $408.82K | $18.68B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
J.M. Smucker (SJM) trades at $113.00, up 3.85% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $1.23 billion for 2025, with negative profit margins, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $123.18 price target, supported by strong cash flow and a 4% dividend yield. Key growth drivers include Uncrustables and coffee brands, while fiscal 2027 sales are expected to decline 3-4%.
SJM presents a mixed outlook: valuation appears reasonable with a P/E of 22.05, but profitability concerns and high debt pose risks. Near-term catalysts include cost controls and brand innovation, yet competitive pressures and weak sales guidance may limit upside. The stock offers income via dividends, but investors should weigh execution risks against potential margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
